Phase IIa Results Announced for Psoriasis Treatment

Phase IIa Results Announced for Psoriasis Treatment

DURECT Corporation announced top-line results from its phase IIa clinical trial of DUR-928 for mild to moderate plaque psoriasis. While the drug was well tolerated, it did not demonstrate a meaningful benefit over placebo in the trial, and DURECT will no longer be pursuing this indication, instead focusing on trials of DUR-928 for nonalcoloholic steatohepatitis (NASH). Will our extensive experience with clinical trials, Yourway knows the importance of agile decision making to determine which trials to terminate and which to pursue.

Back to Index

Upcoming Event


August 24-26, 2020
Brussels, Belgium



The New Normal in Clinical Trial Protection

Open chat
Come chat with us!
Hello! How can I help you?